Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

INTRODUCTION: Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally admin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lung Cancer
Päätekijät: Campbell, Nicholas P., Kunnavakkam, Rangesh, Leighl, Natasha, Vincent, Mark D., Gandara, David R., Koczywas, Marianna, Gitlitz, Barbara J., Agamah, Edem, Thomas, Sachdev P., Stadler, Walter M., Vokes, Everett E., Kindler, Hedy L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319647/
https://ncbi.nlm.nih.gov/pubmed/22831987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.06.011
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia